T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models

Journal:
Journal of Clinical Investigation
Published:
DOI:
10.1172/jci196613
Affiliations:
7
Authors:
29
Go to article
Institutions Authors Share
Shanghai General Hospital, SJTU, China
21.000000
21.000000
21.000000
 0.72
Shanghai Pharma (SPH), China
4.000000
 0.14
Kuaixu Biotechnologies, China
3.000000
 0.10
Suzhou CureMed Biopharma, China
1.000000
 0.03
Interested in Immunology?